Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $82,796.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 700 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total transaction of $82,796.00. Following the completion of the transaction, the insider now owns 18,831 shares of the company’s stock, valued at approximately $2,227,330.68. This represents a 3.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Julie Cooke also recently made the following trade(s):

• On Thursday, February 13th, Julie Cooke sold 1,551 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $116.78, for a total transaction of $181,125.78.
• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.89, for a total value of $266,028.60.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $115.02 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market cap of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33. The firm has a 50 day simple moving average of $138.09 and a 200-day simple moving average of $130.82.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, equities analysts expect that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Golden State Wealth Management LLC purchased a new position in Neurocrine Biosciences in the 4th quarter valued at about $25,000. Huntington National Bank grew its position in shares of Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after buying an additional 97 shares during the last quarter. Brooklyn Investment Group grew its holdings in shares of Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares during the last quarter. GeoWealth Management LLC grew its stake in Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock worth $35,000 after buying an additional 102 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the topic of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research note on Friday, February 7th. Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They set a “hold” rating and a $138.00 price target for the company. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $166.90.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.